Specifically, loss of EZH2 promotes AML initiation, reflected in low-frequency loss-of-function mutations in myeloid neoplasms (47–49), and the observed acceleration of AML transformation from pre-malignant myeloproliferative neoplasms (MPN) (50, 51). Here, EZH2 is linked to acute myeloid leukemia.